Recently Featured

RevMed Achieves Remarkable Milestone Amid FDA Reclassification of Peptides

April 22, 2026
RevMed has reported an impressive surge in its market performance, signaling a significant breakthrough in its product offerings. This success comes at a time when the FDA is poised to reclassify peptides, a move that could reshape the landscape for peptide-based therapies. The implications of this reclassification are profound, as it may streamline regulatory pathways…

UCB to Acquire Neurona for Up to $1.2B, Expanding Seizure Treatment Portfolio

April 22, 2026
UCB has announced its intention to acquire Neurona Therapeutics for a deal valued at up to $1.2 billion, a strategic move aimed at enhancing its portfolio in the epilepsy treatment landscape. This acquisition is particularly significant as it allows UCB to diversify beyond its current focus on small molecule therapies, integrating a promising cell therapy…

Targeted Gene Delivery Calms Lung Inflammation in Respiratory Infection Mouse Models

April 22, 2026
A group of scientists have developed a targeted delivery platform that can induce anti-inflammatory cytokine expression in mouse lungs, which helps restrict tissue damage from respiratory infections without triggering systemic side effects. Full details are published in Science Immunology in a paper titled “Gene delivery of immunomodulatory cytokines to the lung preserves respiratory function during…

Revolution Medicines Reports Significant Survival Benefit in Pancreatic Cancer Study

April 21, 2026
Revolution Medicines announced a stunning survival benefit for its experimental drug, daraxonrasib, in a Phase 3 pancreatic cancer study this week. Patients with advanced pancreatic adenocarcinoma treated with the daily pill lived a median of 13.2 months, compared to just 6.7 months for those receiving standard chemotherapy. This groundbreaking data positions Revolution Medicines to apply…

Ongoing Cases